What is the evidence for Thymosin Beta-4?
Thymosin beta-4 has early human development work and extensive preclinical biology, but that record does not establish routine systemic recovery use or equivalence to TB-500 products.
DIRECT ANSWER
Thymosin Beta-4 evidence summary.
Thymosin beta-4 has early human development work and extensive preclinical biology, but that record does not establish routine systemic recovery use or equivalence to TB-500 products.
Reviewed August 8, 2026. Each statement links to its evidence record, followed by the primary and official sources used for this answer.
Phase 1 systemic exposure and small phase 2 topical ophthalmic studies exist, but no broad recovery indication is established.
Open evidence recordActin binding, cell migration, angiogenesis, and repair models form a substantial preclinical literature.
Open evidence recordFull-length thymosin beta-4, recombinant products, topical formulations, and TB-500 are not interchangeable evidence entities.
Open evidence recordPRIMARY & OFFICIAL SOURCES
Sources for this answer.
3 source records, with duplicates removed.